Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

BACKGROUND: Accurately monitoring and collecting drug adherence data can allow for better understanding and interpretation of the outcomes of clinical trials. Most clinical trials use a combination of pill counts and self-reported data to measure drug adherence, despite the drawbacks of relying on t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bain, Earle E, Shafner, Laura, Walling, David P, Othman, Ahmed A, Chuang-Stein, Christy, Hinkle, John, Hanina, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340925/
https://www.ncbi.nlm.nih.gov/pubmed/28223265
http://dx.doi.org/10.2196/mhealth.7030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340925/
https://www.ncbi.nlm.nih.gov/pubmed/28223265
http://dx.doi.org/10.2196/mhealth.7030

Ejemplares similares